Endocrine Metabolic & Immune Disorders-drug Targets

Endocrine Metabolic & Immune Disorders-drug Targets

内分泌代谢和免疫疾病-药物靶点

  • 4区 中科院分区
  • Q3 JCR分区

期刊简介

《Endocrine Metabolic & Immune Disorders-drug Targets》是由Bentham Science Publishers B.V.出版社于2001年创办的英文国际期刊(ISSN: 1871-5303,E-ISSN: 2212-3873),该期刊长期致力于内分泌学与代谢领域的创新研究,主要研究方向为ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY。作为SCIE收录期刊(JCR分区 Q3,中科院 4区),本刊采用OA未开放获取模式(OA占比0.0041...%),以发表内分泌学与代谢领域等方向的原创性研究为核心(研究类文章占比65.91%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在176篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Endocrine Metabolic & Immune Disorders-drug Targets审稿周期约为 。该刊近年未被列入国际预警名单,年发文量约176篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 176 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ENDOCRINOLOGY & METABOLISM 内分泌学与代谢 IMMUNOLOGY 免疫学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ENDOCRINOLOGY & METABOLISM SCIE Q3 134 / 186

28.2%

学科:IMMUNOLOGY SCIE Q4 144 / 181

20.7%

学科:PHARMACOLOGY & PHARMACY SCIE Q3 222 / 354

37.4%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ENDOCRINOLOGY & METABOLISM SCIE Q4 149 / 186

20.16%

学科:IMMUNOLOGY SCIE Q4 139 / 181

23.48%

学科:PHARMACOLOGY & PHARMACY SCIE Q3 265 / 354

25.28%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:4.6 SJR:0.495 SNIP:0.541
学科类别 分区 排名 百分位
大类:Medicine 小类:Endocrinology, Diabetes and Metabolism Q2 119 / 244

51%

大类:Medicine 小类:Immunology and Allergy Q3 131 / 233

43%

期刊发文

  • Transcriptional Profiling of TGF-beta Superfamily Members in Lumbar DRGs of Rats Following Sciatic Nerve Axotomy and Activin C Inhibits Neuropathic Pain

    Author: Zhang, Feng-Ming; Wang, Bing; Hu, Han; Li, Qing-Yi; Chen, Hao-Hao; Luo, Li-Ting; Jiang, Zuo-Jie; Zeng, Mei-Xing; Liu, Xing-Jun

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2023; Vol. 23, Issue 3, pp. 375-388. DOI: 10.2174/1871530322666221006114557

  • A Novel Compound Heterozygous Gene Mutation of Dolichol Kinase Deficiency (DOLK-CDG)

    Author: Yu, Shufeng; Zhang, Ying; Chen, Zhihong; Song, Jiye; Wang, Caixia

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2023; Vol. 23, Issue 2, pp. 235-241. DOI: 10.2174/1871530322666220607123739

  • Engineered BMSCs-Derived Exosomal miR-542-3p Promotes Cutaneous Wound Healing

    Author: Xiong, Qing-Hua; Zhao, Lei; Wan, Guan-Qun; Hu, Yun-Gang; Li, Xiao-Lin

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2023; Vol. 23, Issue 3, pp. 336-346. DOI: 10.2174/1871530322666220523151713

  • CD163 in Macrophages: A Potential Biomarker for Predicting the Progression of Diabetic Nephropathy based on Bioinformatics Analysis

    Author: Wang, Xiaoxia; Li, Rui; Liu, Ting; Jia, Yanyan; Gao, Xingxing; Zhang, Xiaodong

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2023; Vol. 23, Issue 3, pp. 294-303. DOI: 10.2174/1871530322666220616102754

  • The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel

    Author: Wang, Tingting; Feng, Jie; Zhou, Liying; Zhao, Ting; Zhang, Huilan; Shen, Hao; Xu, Li; Sun, Li; Wu, Jianhua; Li, Hongjian; Yu, Luhai

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2023; Vol. 23, Issue 2, pp. 196-204. DOI: 10.2174/1871530322666220523142229

  • Betulinic Acid Exerts Anti-inflammatory Activity in Human Periodontal Ligament Cells Stimulated with Lipopolysaccharide and/or High Glucose

    Author: Hu, Ping; Zhu, Chunxia

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2023; Vol. 23, Issue 1, pp. 95-104. DOI: 10.2174/1871530322666220509231119

  • A Review of Structural Features, Biological Functions and Biotransformation Studies in Adipose Tissues and an Assessment of Progress and Implications

    Author: Chu, Ting; Yang, Mao Sheng

    Journal: ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS. 2023; Vol. 23, Issue 1, pp. 12-20. DOI: 10.2174/1871530322666220827145241

  • Testicular injury attenuated by rapamycin through induction of autophagy and inhibition of endoplasmic reticulum stress in streptozotocin-induced diabetic rats.

    Author: Shi W1, Guo Z2, Yuan R1.

    Journal: Endocr Metab Immune Disord Drug Targets. 2019 Jan 1. doi: 10.2174/1871530319666190102112844. [Epub ahead of print]